SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves selloff is being discussed alongside concerns about its heavy debt load, rising borrowing costs and whether AI demand and contract backlog can support its financing needs, with HSBCs bearish assessment adding to the pressure. Traders are split between viewing the balance-sheet risks and insider selling as reasons for further downside and arguing that strong demand, the backlog and Nvidia ties make the drop a buying opportunity.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lilly is drawing attention after breaking to a new high, with traders linking the rally to European regulatory backing for its Foundayo obesity pill and broader optimism about its GLP-1 business. Bulls are celebrating the breakout and healthcares defensive appeal, while skeptics point to possible profit-taking, competition from Novo and the upcoming earnings report.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows is fueling a heavily bearish conversation, with traders tying its political-proxy appeal to concerns about Trumps approval and the midterms, while questioning the companys business traction. A smaller bullish contingent sees a possible trading bounce and points to the pending TAE fusion deal as a potential pivot.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers rally to a 52-week high is driving discussion, with traders citing momentum and rotation into defensive, dividend-paying pharma amid broader market weakness. Bulls see a potential breakout, while skeptics point to resistance and say a fresh company-specific catalyst is needed.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to elevated crude prices and fears that Middle East shipping or energy-infrastructure attacks could disrupt supply, while weighing possible diplomacy and Russian supply relief. The community is split between bulls focused on geopolitical risk and bears expecting the risk premium to fade, with some also warning that contract-roll effects and an extended run may amplify volatility.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, drawing attention to the drugs potential but also to concerns about modest symptom improvement, agitation-related side effects, and discontinuations. Traders are divided, with some viewing the move as a fading bounce and adding shorts while others point to bullish analyst commentary.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is drawing attention after strong Q3 results and an upbeat outlook, with AI-related demand and growing Vertical Power Delivery royalty revenue reinforcing the growth story. Traders are weighing that strength against questions about one-time royalty catch-up payments, production capacity, and the earnings-per-share miss, contributing to a volatile reaction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is selling off despite a third-quarter earnings and revenue beat and a new multiyear buyback, as traders focus on the narrowed profit outlook with its midpoint unchanged and declining U.S. sales and market share. Some see the decline as a buying opportunity given cash generation and capital returns, while others argue the outlook failed to justify the valuation.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is drawing attention after quarterly results beat expectations and the company raised its full-year outlook, citing strong aerospace and defense demand and a record backlog. Traders broadly praised the results, while some questioned why the share-price reaction was muted.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces quarterly results beat expectations and the company raised its outlook, but shares fell as traders weighed rising costs, weaker cash flow and a loss in its insurance business. The reaction has split the community between buyers calling the selloff unjustified after a strong report and bears focused on the cost pressures and weak price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround 

Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial

Equity

Prelude expects patient enrollment to begin in Q4 2026, starting with monotherapy dose escalation before advancing to combination cohorts.


Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million.
Prelude Therapeutics (NASDAQ:PRLD) shares movedread more...

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why

Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Prelude Therapeutics (PRLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Given Consensus Recommendation of "Hold" by Analysts

Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) has earned an average rating of 'Hold' from the five brokerages that are presently covering the stock, Marketbeat.com reports. One...

Prelude Therapeutics (NASDAQ:PRLD) Coverage Initiated by Analysts at D. Boral Capital

D. Boral Capital initiated coverage on shares of Prelude Therapeutics in a research note on Monday. They set a 'buy' rating and a $9.00 price target on the stock...

Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research

Zacks Research raised Prelude Therapeutics to a "hold" rating in a research report on Tuesday...

Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday

Prelude Therapeutics (NASDAQ:PRLD) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-prelude-therapeutics-incorporated-stock...

Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.

Prelude Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Under the agreement, Lilly will supply abemaciclib, marketed as Verzenio, and Imlunestrant, marketed as Inluriyo.</li><li>The Phase 1 trial will evaluate combinations of PRT13722, an oral KAT6A selective degrader, with these medicines in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer.</li><li>The FDA cleared Prelude to proceed with the study under its Investigational New Drug (IND) application.</li></ul>Prelude Therapeutics (PRLD) announced a clinical trial collaboration and supply agreement with Eli Lilly and Company (LLY) on Tuesday to evaluate its experimental breast cancer drug PRT13722 in combination with two Lilly medicines.At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/PRLD">PRLD shares</a> were down more than 7%, while&nbsp;<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> traded 1.5% lower. The iShares Biotechnology ETF (<a href="https://stocktwits.com/symbol/IBB">IBB</a>) declined over 1.5%.<h2 class="st-heading-2">What Does The Lilly Collaboration Involve?</h2>Under the agreement, Lilly will supply Abemaciclib, marketed as Verzenio, and Imlunestrant, marketed as Inluriyo. The Phase 1 trial will evaluate combinations of PRT13722, an oral KAT6A selective degrader, with these medicines in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer.The FDA cleared Prelude to proceed with the study under its Investigational New Drug (IND) application. The company expects enrollment to begin in the fourth quarter of 2026, starting with monotherapy dose escalation before advancing to combination cohorts.Sean Brusky, Prelude’s chief business and strategy officer, said: “Our preclinical data demonstrate that selectively degrading KAT6A has the potential to improve upon the efficacy and hematologic toxicity seen with dual KAT6A/B inhibitors.” He added that the approach could enable combination treatments that may advance the standard of care in earlier lines of therapy.<h2 class="st-heading-2">What Has Prelude Reported About PRT13722?</h2>At the&nbsp;American Association for Cancer Research (AACR) 2026 Annual Meeting in April, Prelude presented preclinical data showing that PRT13722 produced durable complete tumor regressions as a monotherapy in HR+/HER2- breast cancer cell-line-derived and patient-derived xenograft models at well-tolerated doses.The company also reported synergy when PRT13722 was combined with endocrine therapies, CDK4/6 inhibitors and PI3K inhibitors across HR+ breast cancer models, including ESR1-mutated and acquired therapy-resistant cancer cells.Prelude said the candidate demonstrated an improved hematological safety profile compared with prifetrastat, a dual KAT6A/B inhibitor, in preclinical testing.&nbsp;<h2 class="st-heading-2">How Retail Views PRLD, LLY</h2>Retail sentiment for both PRLD and LLY on Stocktwits remained in ‘Bearish’ territory over the past 24 hours.One Stocktwits user praised PRLD’s collaborations.<stembedurl>https://stocktwits.com/Bernardbaruch1/message/666375649</stembedurl>PRLD shares have risen more than 48% year to date, while LLY shares have gained more than 8% over the same period.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/robinhood-gets-a-price-target-hike-from-truist-as-wall-street-s-earnings-outlook-improves/cZxBnkORBYg">Robinhood Gets A Price Target Hike From Truist As Wall Street’s Earnings Outlook Improves</a>For updates and corrections, email newsroom@stocktwits.com

Young female scientist working in laboratory (Representative image courtesy of Solskin via Getty Images)

Prelude Therapeutics (PRLD) announced a clinical trial collaboration and supply agreement with Eli Lilly and Company (LLY) on Tuesday to evaluate its experimental breast cancer drug PRT13722 in combination with two Lilly medicines.

iShares Biotechnology ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$3.53
Prev Close	$3.39
Open	$3.38
Dividend Yield	0.00%
50-Day Moving Average	$4.78
Beta	1.89
Avg. Volume	500,491.14
PE Ratio	-4.30

52-Week High	$6.83
52-Week Low	$1.17
Market Capitalization	$270.53M
EPS (Annual)	-$1.29
Price to Book	2.02
Revenue Per Employee	$153,670.89

Feed

News

Sentiment

Earnings

Fundamentals

Info

PRLD Fundamentals